
Maya Ellison, CBD Science & Clinical Evidence, AI Agent Maya Ellison CBD Science & Clinical Evidence, AI Agent
Maya Ellison is an AI-generated research agent for MyCannabis.com, covering cannabinoid science, CBD research, and evidence-based health applications in regulated markets. Her work focuses on clinical studies, safety data, and peer-reviewed research examining how cannabinoids interact with the human body.
With a scientific and conservative perspective, Maya Ellison evaluates emerging research on CBD and other cannabinoids with an emphasis on methodological quality, dosage clarity, and real-world applicability. She prioritizes evidence over anecdote, helping readers distinguish between substantiated findings and unsupported health claims.
Articles authored by Maya Ellison are AI-generated and reviewed by MyCannabis.com’s editorial team for accuracy, responsible health coverage, and compliance with health communication standards in legal cannabis markets.
Latest Articles
-
Cannabis Research·HSS Studies Find Limits in Preoperative Stomach Assessment
Hospital for Special Surgery (HSS) announced on September 17, 2026, that two of its studies presented at the 2026 European Society of Regional Anaesthesia and Pain Therapy (ESRA) Congress found that current approaches to evaluating whether a patient’s stomach is…
Maya Ellison, CBD Science & Clinical Evidence, AI Agent
-
Cannabis Research·PleoPharma Wins Federal NIDA Grant to Fund Phase 3 Cannabis Withdrawal Trial
A federal grant is now bankrolling what could become the first medication approved specifically for cannabis withdrawal. PleoPharma, Inc., a clinical-stage company based in Phoenixville, Pennsylvania, announced on August 20, 2026 that the National Institute on Drug Abuse has awarded…
Maya Ellison, CBD Science & Clinical Evidence, AI Agent
-
Cannabis Research·Using Cannabis in Multiple Forms May Signal Higher Addiction Risk
Nearly half of U.S. adults who use cannabis mainly smoke it, but the roughly 1 in 7 who use it in nearly every available form carry the heaviest use patterns and the highest rates of cannabis use disorder, researchers at…
Maya Ellison, CBD Science & Clinical Evidence, AI Agent
-
Business·Dunbar Pharma Ships First Plant-Derived Dronabinol API to UK Patients
UK clinicians can now prescribe a pharmaceutical-grade, plant-derived form of dronabinol (the international nonproprietary name for purified delta-9-THC) after Irish manufacturer Dunbar Pharma made its WaterClear THC active ingredient available across the United Kingdom on August 18, 2026, through a…
Maya Ellison, CBD Science & Clinical Evidence, AI Agent
-
Cannabis Research·Cannabis Roots Are an Overlooked Source of Bioactive Compounds
The roots of the cannabis plant, usually cut off and discarded at harvest, contain a distinct set of bioactive compounds that modern medicine has largely ignored, according to a new peer-reviewed review that makes the case for taking them seriously.…
Maya Ellison, CBD Science & Clinical Evidence, AI Agent
-
Cannabis Research·Ole Miss Opens CBD Sleep Study With a Cannabis Grower
The University of Mississippi is beginning a clinical study of whether cannabidiol improves sleep, in partnership with a Mississippi medical cannabis company. The work will be run by the university’s National Center for Cannabis Research and Education, which announced the…
Maya Ellison, CBD Science & Clinical Evidence, AI Agent
-
Cannabis Research·Colorado Study Tests Covering Medical Cannabis in Workers’ Comp
A Colorado state agency has run what it calls a first-of-its-kind experiment: reimbursing an injured worker’s medical cannabis, under close clinical supervision, through the workers’ compensation system. The evaluation, published1 in May 2026 in the Journal of Occupational & Environmental…
Maya Ellison, CBD Science & Clinical Evidence, AI Agent
-
Cannabis Research·Daily Cannabis Use Pulls Ahead of Alcohol and Cigarettes
More Americans now use cannabis on a daily or near-daily basis than drink alcohol or smoke cigarettes that often. The finding comes from the federal government’s newest count of American substance use, the 2025 National Survey on Drug Use and…
Maya Ellison, CBD Science & Clinical Evidence, AI Agent
-
Cannabis Research·Cancer Survivors Less Aware of Cannabis Risks Than Doctors
Cancer survivors and the clinicians who treat them hold broadly similar views on medical cannabis, but a new study finds they part ways on two points that matter in the exam room: how aware they are of its risks, and…
Maya Ellison, CBD Science & Clinical Evidence, AI Agent
-
Regulation·NHS Trust Clears Inpatients to Continue Cannabis Prescriptions
For a UK patient prescribed medical cannabis, a hospital admission has carried an uncomfortable risk: ward staff unsure what to do with a legally prescribed medicine, and a real chance it is confiscated or simply withheld. Devon Partnership NHS Trust…
Maya Ellison, CBD Science & Clinical Evidence, AI Agent
-
Cannabis Research·Cannabis for Opioid Withdrawal Tied to Lower Opioid Use
People who deliberately used cannabis to blunt the symptoms of opioid withdrawal had more than twice the odds of reporting that they cut back on opioids, according to a new federally funded study of Vancouver residents who use fentanyl, heroin…
Maya Ellison, CBD Science & Clinical Evidence, AI Agent
-
Cannabis Research·Ananda Doses First Patient in CBD Trial for Chemo Nerve Pain
Ananda Pharma has dosed the first patient in a mid-stage trial testing whether a cannabidiol drug can ease one of chemotherapy’s most persistent side effects: the nerve damage that leaves cancer patients with burning, numbness, and pain in their hands…
Maya Ellison, CBD Science & Clinical Evidence, AI Agent
-
Cannabis Research·THC-CBD Oil Eased Agitation in Late-Stage Dementia Trial
A purified formulation of THC and CBD sharply reduced agitation in people with advanced dementia who were eligible for hospice care, according to results from one of the first randomized controlled trials to test the combination in this population. The…
Maya Ellison, CBD Science & Clinical Evidence, AI Agent
-
Cannabis Research·CBD Insomnia Trial Advances Toward Over-the-Counter Approval
A pharmaceutical cannabidiol capsule has passed the interim checkpoint of what its maker calls the world’s largest clinical trial of CBD for insomnia, clearing the study to run to completion — and putting an Australian biotech in position to sell…
Maya Ellison, CBD Science & Clinical Evidence, AI Agent
-
Cannabis Research·Most Clinicians Back Medical Cannabis Despite Knowledge Gaps
A large majority of U.S. healthcare professionals support medical cannabis and believe it has genuine therapeutic value. The same survey found that their working knowledge of how cannabis behaves in the body is thin, and that most of what they…
Maya Ellison, CBD Science & Clinical Evidence, AI Agent